Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Lowered by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 43.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,611 shares of the biopharmaceutical company's stock after selling 7,488 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Intra-Cellular Therapies were worth $803,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. True Wealth Design LLC acquired a new position in Intra-Cellular Therapies in the third quarter worth about $32,000. GAMMA Investing LLC lifted its holdings in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. Finally, Quarry LP increased its holdings in shares of Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after acquiring an additional 1,300 shares during the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank of Canada restated a "sector perform" rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Thursday, March 20th. They set a "hold" rating on the stock. Leerink Partnrs downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Finally, Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price target for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $106.08.

Remove Ads

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI remained flat at $131.70 on Tuesday. The stock had a trading volume of 1,133,068 shares, compared to its average volume of 1,336,142. The firm has a market capitalization of $14.00 billion, a P/E ratio of -151.38 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.71. The company's 50 day moving average price is $128.70 and its 200-day moving average price is $98.18.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.